Recordati, IT0003828271

Recordati stock at EUR 53.15 on September 28, 2026, up 0.19 percent

Published on 09/28/2026 at 23:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Recordati stock last traded at EUR 53.15 on September 28, 2026, up 0.19 percent. The company also announced a EUR 250,000 pediatric oncology research grant.

Moderne Pharma-Produktionsanlage mit Edelstahltanks und Glasfassade bei Tageslicht
Recordati S.p.A. (IT0003828271) betreibt moderne Pharma-Produktionsanlagen mit hochwertiger Fertigungstechnik am Firmensitz in Mailand, Italien, Illustration mit AI erstellt.

Trading session

Recordati stock last traded at EUR 53.15 on Euronext Milan at 15:35:04 UTC on September 28, 2026. The share was up EUR 0.10, or 0.19 percent, from the previous close of EUR 53.05.

Research award announced

On September 17, 2026, Recordati S.p.A. announced Dr. Laura Broutier as the winner of the 12th International Prize for Scientific Research Arrigo Recordati. The company awarded a EUR 250,000 research grant for the DISARMS project, which focuses on fusion-negative rhabdomyosarcoma in pediatric oncology, according to the Recordati release distributed by GlobeNewswire.

The release said the winning project aims to investigate how tumor cells survive chemotherapy and contribute to relapse and metastasis. The award ceremony took place in San Antonio, Texas, during the 58th Annual SIOP Congress, the company said in the same release.

Tender-offer dispute

A Business Wire release said shareholder Palliser Capital urged Recordati’s board to withdraw support for Respighi BidCo’s EUR 51.29-per-share tender offer. Palliser called for consideration of at least EUR 60 per share and said Recordati’s independent directors had recommended against the transaction.

Disclaimer...

en | IT0003828271 | RECORDATI | boerse | 70195641 | bgmi